EMPA-REG OUTCOME: Empagliflozin Cuts Insulin Need in Type 2 Diabetes EMPA-REG OUTCOME: Empagliflozin Cuts Insulin Need in Type 2 Diabetes
The SGLT2 inhibitor reduced the need to start insulin treatment or intensify existing insulin treatment compared with placebo in a post-hoc analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
DCRI-collaboration-empact-mi
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin ’s effects following an acute myocardial infarction Ischemic heart disease, including myocardial infarction, is the leading cause of death in the world1EMPACT-MI is the first trial in the SGLT2 inhibitor class to investigate the prevention of heart failure after acute myocardial infarction in adults with and without diabetesThe trial is part of the EMPOWER clinical trial program, the broadest and most comprehensive of any SGLT2 inhibitor, exploring the impact of empagliflozin on the lives of p...
Source: Boehringer Ingelheim Corporate News - May 26, 2020 Category: Research Source Type: news
Fda-crl-t1d
US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 20, 2020 Category: Research Source Type: news
FDA-Fast-Track-chronic-kidney-disease
U.S. FDA grants Fast Track designation to empagliflozin for the treatment of chronic kidney disease (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 12, 2020 Category: Research Source Type: news
Trijardy XR (Empagliflozin, Linagliptin, and Metformin Hydrochloride Extended-release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 14, 2020 Category: Drugs & Pharmacology Source Type: news
Trijardy XR (Empagliflozin, Linagliptin, and Metformin Hydrochloride Extended-release Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 5, 2020 Category: Drugs & Pharmacology Source Type: news
Monthly News Roundup - January 2020
Trijardy XR: A Triple Drug Combo Approved for Type 2 Diabetes
In January, the US Food and Drug Administration (FDA) approved once-daily Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended release tablets) to lower blood... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2020 Category: Pharmaceuticals Source Type: news
FDA OKs New Triple-Combo Pill, Trijardy XR, for Type 2 Diabetes FDA OKs New Triple-Combo Pill, Trijardy XR, for Type 2 Diabetes
The once-daily treatment comprises empagliflozin (Jardiance), linagliptin (Tradjenta), and extended-release metformin hydrochloride. It will be available in four different dosages.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 28, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news
FDA Approves Trijardy XR (empagliflozin/linagliptin/metformin) for Type 2 Diabetes in Adults
RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 27, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets) to lower blood sugar in adults with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 27, 2020 Category: Drugs & Pharmacology Source Type: news
Lilly, Boehringer's Jardiance has heart failure trial setback
Boehringer Ingelheim and Eli Lilly announced failing results in two trials evaluating Jardiance in adults with chronic heart failure. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 13, 2019 Category: Pharmaceuticals Source Type: news
EMPERIAL-heart-failure-toplineresults
Boehringer Ingelheim and Lilly provide update on empagliflozin phase III exercise ability studies in chronic heart failure (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 13, 2019 Category: Research Source Type: news
EMPRISE-interim-analysis
Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonistsThis analysis on effectiveness also shows empagliflozin was associated with a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors or GLP-1 receptor agonists1 A second analysis on healthcare resource utilisation shows empagliflozin was associated with a reduced risk in all-cause hospitalisations compared with DPP-4 inhibitors2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 17, 2019 Category: Research Source Type: news
FDA Panel Rejects Empagliflozin for Use in Type 1 Diabetes FDA Panel Rejects Empagliflozin for Use in Type 1 Diabetes
The FDA advisers said the pivotal approval study was too short and did not involve enough patients to characterize efficacy or safety.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 14, 2019 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Source Type: news
Empulse
Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilisedEMPULSE is a superiority study that will assess the clinical benefit, safety and tolerability of 10 mg daily empagliflozin in acute heart failure1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 12, 2019 Category: Research Source Type: news
' Best in Class' Diabetes Drugs Compared in Head-to-Head Trial'Best in Class' Diabetes Drugs Compared in Head-to-Head Trial
A1c was reduced significantly more with oral semaglutide versus empagliflozin in a comparison of the type 2 diabetes drugs, but the former still lacks evidence of CV efficacy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 11, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
